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T
his note challenges the current idea
that a key role of T cells in tumor
regression is to directly kill tumor cells. It
favors the view that TIL are keys but act
indirectly by helping other immune cells
to damage the tumor and its stroma.
The Current Model and its Limits
It is now clear that solid tumors can be
infiltrated by immune cells able to play
both pro- and anti-tumoral roles. Based on
t h ef a c tt h a ti nm o s t( t h o u g hn o ta l l )
human cancers, a good prognosis is
associated with the presence of tumor-
infiltrating lymphocytes (TIL), the current
model places T cells as central actors of the
antitumor immune action, i.e., they are
expected to directly kill tumor cells, and to
be the main final effectors of tumor cell
death (Fig.1, left). A frequently overlooked
paradox is that TIL present in primary
tumors cannot be the ones that will attack
tumors in patients after resection of their
primary tumor; at most, they are indicative
of an ongoing T cell response, hopefully
with clones persisting in patients after
resection, with a role in immune surveil-
lance (an issue distinct from tumor regres-
sion) and a better outcome.
In many murine tumor models, tumor
growth is accelerated when animals are
depleted of circulating T cells (almost
always CD8). The importance of perforin
in this issue remains controversial.
1,2 The
fact that tumors grow despite the presence
of TIL is generally explained by the fact
that TIL become unresponsive in an
immunosuppressive microenvironment
and thus, cannot do their job to attack
tumor cells. Another frequent argument
in favor of a direct cytotoxic effect of
anti-tumoral T cells is the therapeutic
success of adoptive transfer of anti-tumor
T lymphocytes in some human cancers.
3
In these trials, the existence of interactions
between transferred T cells and tumor cells
has been illustrated but such interactions
have never been quantified.
However, in a murine model of adopt-
ive transfer of T cells, it has been shown
that when tumors melt, the vast majority
of transferred T cells accumulated at the
periphery of the tumor, the tumor nest
being mainly invaded by Gr1
+ innate cells
(neutrophils and/or inflammatory mono-
cytes).
4 In addition, the slow rate at which
cytotoxic T cells can kill tumor cells in
situ
5 is hardly compatible with the idea
that such an effect may be efficient against
rapidly dividing tumor cells. Conversely,
innate cells like NK, cdT cells and
macrophages act rapidly to kill and/or
phagocyte. In addition, efficacy of mono-
clonal antibodies in cancer therapy is
strongly associated with Fc receptor-
dependent mechanisms and cell-mediated
cytotoxicity which are properties shared by
these potent innate effectors.
Thus, all these observations do not fit
well with the current model of TIL killing
directly tumor cells and of cytotoxic T cells
being the main final effectors against
tumor cells. Despite this, the current
model is largely prevailing, with major
consequences. Indeed, even if other con-
cepts are taken into account, such as the
importance of limiting immunosuppres-
sion,
6 or making the appropriate combina-
tions of chemo- and immunotherapy,
7
most clinical trials of active immuno-
therapy still aim at generating highly
reactive T cells as the main way to
optimize a tumor attack. We consider that
this point of view needs to be revisited.
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Environment in the Tumor
Data obtained in human and murine
tumors are consistent with the idea that
the anti-tumoral action of T cells is
indirect. The localization of immune cells
in human tumors is only known for
tumors in progression, when they are
resected. In these tumors, when present,
the highest density of TIL is found in the
peritumoral stroma, not in the cancer
nest itself (ref. 8 and Salmon et al., in
revision). A good prognosis is in general
not associated with abundant CD8 in
the cancer nest (even if there are a few
exceptions, such as seen in ref. 9), but
with abundant T cells in the stroma,
either CD4
10 or coexistence of CD4 and
CD8.
11,12 Even NK cells, when present,
are more abundant in the stroma.
13 It is
difficult to draw firm conclusions con-
cerning the ability of such cells to
contribute to tumor regression, since, as
mentioned above, these data only char-
acterize the properties of cells that will
participate in cancer immunosurveillance
after tumor resection. However, if an
efficient anti-tumoral immune response
able to lead to tumor regression could be
triggered, it would have to start with such
an intratumoral distribution. Data
obtained with murine tumors, and further
developed below, are also in favor of the
idea that the anti-tumoral action of T cells
is mostly indirect.
The peritumoral stroma is a complex
ecosystem and a key battlefield. Tumor
cells are embedded in a stroma providing
nutrients and growth factors. The vascu-
lature, although built out of control, feeds
the tumor (blood) and allows metastasic
spread (lymph). Tumor-associated fibro-
blasts secrete growth factors and extra-
cellular matrix elements, mandatory for
tumor growth and emigration. Tissue
remodeling and fibrosis are supported by
myeloid cells (macrophages and neutro-
phils) making metalloproteases, angiogenic
factors and TGFβ. This last molecule
contributes to suppress an aggressive
action of the immune system. Most
studies consider only this first set of tumor
stroma features (for a review, see e.g.,
ref. 14).
However, and despite its absence of an
obvious spatial organization, the same
Figure1. Cellular and molecular actors in the tumor ecosystem after induction of an anti-tumor immune response. In the classical scenario (left), there is
no specific structuration of the tumor. All the cellular actors are viewed as protumoral, and once an anti-tumor response is induced, cytotoxic T and NK
cells are considered as the sole final effectors, acting through direct tumor cell killing. In a revisited scheme (right), tumor and stromal regions are clearly
distinct, with most immune cells in the stroma, and a large spectrum of pro- and anti-tumoral effectors exist. The action of T cells is to a large extent
indirect, and involves cellular interactions in the stroma. This scheme does not take into account the time sequence following which various immune
cells are recruited at the tumor site to participate to tumor destruction.
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viewed as a tertiary lymphoid organ,
starting point of an efficient anti-tumor
response. Thus, Eberl and colleagues have
shown that lymphoid stromal cells, which
contribute to the normal development of
secondary lymphoid organs, are present in
the peritumoral stroma.
15 These lymphoid
stromal cells could interact with myeloid
cells to attract many different cell types
and start the auto-organization of a
lymphoid organ. In line with this, the
presence of lymphoid-like structure in
human non-small cell lung carcinoma has
been associated with a better prognosis.
16
It seems reasonable to conclude that
multiple cellular interactions taking place
in this microenvironment could cooperate
for the anti-tumor effector phase (Fig.1,
right). In particular, rather than acting as
direct killers of tumor cells, CD8 T cells
may act through the release of various
cytokines, and could activate/recruit other
immune cells at the tumor site. IFNc can
activate macrophages, and tissue-infiltrat-
ing neutrophils are very potently triggered
to release H2O2 by TNFa produced by
lymphocytes or macrophages.
17 NK cells
are also able to produce IFNc and to
activate other effectors, or to help the
maturation of dendritic cells.
18 A con-
sequence of this T cell contribution would
be the triggering of an inflammatory
response arising within the stroma.
As a result of the cellular interactions
taking place in the tumor stroma, multiple
activated effectors may target not only
tumor cells but also the tumor vasculature.
Destruction of the microvasculature involv-
ing T cells, granulocytes or macrophages
has been described in mouse models of
transplanted tumors and may involve
IFNc-dependent anti-angiogenesis.
19,20
This is also true for human tumors. For
instance, in a phaseI clinical trial, thegroup
of Dranoff tested the clinical effects of an
anti-CTLA-4 Ab in patients that had been
previously vaccinated with irradiated auto-
logous tumor cells engineered to secrete
GM-CSF.Theyobservedtumorregressions
with necrosis and vasculopathy, associated
with inflammatory cells, particularly at the
periphery of the lesion.
6,21 Although it
remains unclear if neutrophil recruitment
precedes or follows vasculature damage, it is
clear that vasculature damage is a key for
tumor necrosis. Other stromal cells, like
fibroblasts activation protein-a
+ (FAP) cells
may be appropriate targets for immune
cells. Indeed, their destruction facilitates
anti-tumor immune response and tumor
growth control.
22
An anti-tumoral action of T cells within
the stroma cannot be performed by any
type of activated T cell. It requires an
antigen-specificity. Indeed, tumor-specific
T cells are active against the tumor
whereas concanavalin-A-activated T cells
are not.
23 The reason is probably that
cytokine secretion by memory cells is
almost instantaneous (already quite large
four to six hours after stimulation), but it
is expected to cease rapidly when T cells
are no longer stimulated or when they are
stimulated in an immunosuppressive
environment, see e.g. ref. 24. Thus, T
cells need to be reactivated locally, e.g., by
tumor-associated antigens that could be
presented by dendritic cells/macrophages
in the tumor stroma and even by
neutrophils,
17 endothelial cells or fibro-
blasts. The molecular and cellular mechan-
isms for antigen capture and presentation
to CD4 and CD8 T cells in this context
would deserve a careful study. Highly
infiltrated tumors may be of favorable
prognosis in this setting, in that local
concentration of T cells may allow
sustained T cell activation and epitope
spreading in the tumor area as suggested
by T. Boon and colleagues.
25
Together, these data underline that the
role played by anti-tumor specific T cells
in tumor regression could to a large extent
be through a destabilization of the stroma
ecosystem. Like Janus, the tumor stroma is
two-faced. On one hand it may play a pro-
tumoral role, and on the other it may
contribute to its own destruction, and thus
have an anti-tumoral role.
Kinetic dependence of anti-tumoral
actions. If there is a consensus for consider-
ing that macrophages and neutrophils have
an important role for fighting infections, the
same cells are usually considered as detri-
mental for the efficiency of anti-tumor
responses. It seems more appropriate to us
to consider that these innate cells may have
both pro- and anti-tumoral roles. To
understand this apparent paradox, one has
to take into account the importance of
kinetics in immune responses.
The same cellular or molecular actor
may play very different roles in different
contexts, and depending whether their
abundance varies sharply or is sustained.
Efficient immune responses are most often
transient (compare, e.g., acute vs. chronic
infections) with “on” and “off” phases and
positive and negative feedbacks (Fig.2).
Appropriate termination of an immune
response is absolutely essential to prevent a
cytokine storm, organ specific auto-
immune diseases with tissue destruction
and to let wound healing take place.
The same categories of cells and even
molecules may be involved in these “on”
and “off” phases. Forinstance, inthecaseof
tissue injury, macrophages first phagocyte
and kill intruders before repairing collateral
damages. The phenotype of these macro-
phages changes with time.
26 Similarly, if the
chronic presence of neutrophils within
tumors seems to be pro-tumoral, neutro-
phils may also play a major role in anti-
tumoral responses. Indeed, the sudden
immune response triggered by Bacillus
Calmette-Guerin for treating bladder cancer
involves a neutrophil attack.
27,28
Opposite effects may also be exerted by
one molecule on tumor-related pheno-
menon, as illustrated with IFNc.I n
general, a sudden increase of IFNc is
anti-angiogenic, with important conse-
quences for anti-tumoral actions. But the
sustained secretion of IFNc may also be
pro-angiogenic, e.g., for IFNc secreted by
special NK cells in the uterus, that help the
remodelling of the uterine vasculature
necessary for the implantation of the fetus
in the placenta.
29 It is likely that both the
kinetics of IFNc secretion (rapid change
vs. chronicity associated with the devel-
opment of adaptive responses, or desensi-
tization) and the cellular context, are key
to the dominant effect exerted by IFNc.
In conclusion, the view that myeloid
cells and granulocytes may only benefit to
tumors is largely skewed by the time
window that has been most studied:
growing tumors, associated with an
exhausted anti-tumor response, in its
“off,” or repair phase. A simple snapshot
indicating that T cells, macrophages or
neutrophils are abundant in a tumor
provides no information about the phase
of the immune response in which they are
involved, neither on their ability to
348 OncoImmunology Volume 1 Issue 3participate to an anti-tumor attack, if
appropriately stimulated.
Which Scenarios for T Cells and
Other Partners in this Context?
When a primary tumor has developed, the
immune system could be stimulated to
play two roles. One is to contribute to
tumor regression (together with surgery,
chemo- and radiotherapy). The second is
to prolong the dormancy of micrometa-
stases, or even eliminate them. The
mechanisms necessary for these two
actions are not necessarily the same ones.
Concerning a contribution of the immune
system to tumor regression, discussed in
this paper, one can conclude the following
from the above analysis. In order to exploit
the properties of the immune system, one
should trigger a sudden attack that should
rapidly reach some success, as efficient
immune responses are always transient. It
is likely that the intensity of the attack can
be larger if it is local. This would justify
the use of peritumoral vaccination, when-
ever possible. Such a vaccination should
aim at activating a set of cellular actors, not
only T cells. The targeted structure should
not necessarily be tumor cells, but also
components of the stroma (FAP
+ fibro-
blasts or endothelial cells) (see
30 for an
excellent review).
Such a result may be reached by
mimicking in the peritumoral region a
microbial attack, aiming at activating
locally both the innate system and T cells
in an antigen-specific way, if possible.
Such a view has already been pioneered by
William Coley, a century ago.
31 However,
its translation in a clinical protocol
requires a proper design in order to obtain
an efficient, necessarily transient response
always followed by an “off” phase.
Improperly designed, one may trigger an
excessive, counterproductive “off” phase.
It may be helpful to limit the importance
of this “off” phase, e.g., with an anti-
TGFβ.
32
It is obviously important to test this set
of notions in animal models in which
immune stimulations do result in tumor
regression and not only in slowing its
growth, as reported in most papers in
tumor-murine models.
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Figure2. After an initial stimulus (red arrow), immune responses are always transient. The initial and brief “on” phase is followed by a prolonged “off”
phase. For each group of stimulated cells, cytotoxic activities and release of inflammatory cytokines occur only during the on phase, whereas
immunosuppression, fibrosis, vascularisation are favored during the off phase. Within a tissue or a tumor, non-synchronized responses for different
groups of cells may coexist. All types of immune cells may participate to both phases.
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